Elutia(ELUT)

Focus: Elutia is a public biotechnology company specializing in drug-eluting biomatrix technology for cardiovascular, oncology, and other therapeutic areas. The company operates at modest scale with $14M in FY2025 revenue and focuses on implantable and regenerative medical products.

Cardiovascular Oncology Unknown

Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

About Elutia

AI assessmentNot Hiring

No open roles listed right now. Follow Elutia to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

14 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$14M

Key Products

CanGaroo Envelope

Cardiac Disease / Arrhythmias

Growth

Lead cardiac implant envelope product with multiple clinical trial programs underway.

CorMatrix ECM

Cardiovascular Repair (Carotid, Vascular, Pericardial)

Help build intelligence for Elutia

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides liquidity and potential equity upside in a specialized biotech niche
Diversified pipeline across cardiovascular, orthopedic, and oncology indications offers exposure to multiple therapeutic areas
Specialized expertise in drug-eluting biomatrix technology is a differentiated technical skill set

Watch Out For

Revenue declined 44% year-over-year ($25M to $14M) with significant operating losses ($-54M in FY2025), raising sustainability concerns
Only 1 active job opening and extremely limited hiring activity suggest organizational stagnation or downsizing phase
Pipeline lacks clear clinical trial phase data and regulatory catalyst visibility, indicating early-stage or stalled programs

Generated by Claude from Elutia's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Extracellular matrix platform deployed across multiple cardiovascular indications with post-market study ongoing.

ViBone

Spondylosis / Spondylolisthesis

Growth

Orthopedic bone regeneration product addressing spinal degenerative disease.